Trial Profile

A Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 24 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Tebotelimab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors ZAI Lab

21 Jan 2023 Results (At data cut-off as of 26 Feb 2022, n=27 ) in patients with metastatic GC, presented at the 2023 Gastrointestinal Cancers Symposium
25 May 2022 Status changed from recruiting to discontinued.
02 Nov 2021 According to an MacroGenics media release, Zai Lab enrolled the first patient in an endometrial cancer cohort in October 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com